107 related articles for article (PubMed ID: 31892563)
1. Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.
Wendt EHU; Schoenrogge M; Vollmar B; Zechner D
Anticancer Res; 2020 Jan; 40(1):153-160. PubMed ID: 31892563
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer.
Moir JAG; Long A; Haugk B; French JJ; Charnley RM; Manas DM; Wedge SR; Mann J; Robinson SM; White SA
Pancreas; 2020; 49(10):1364-1371. PubMed ID: 33122526
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells.
Han X; Sheng X; Jones HM; Jackson AL; Kilgore J; Stine JE; Schointuch MN; Zhou C; Bae-Jump VL
J Hematol Oncol; 2015 Jan; 8():2. PubMed ID: 25631326
[TBL] [Abstract][Full Text] [Related]
4. Impact of diabetes type II and chronic inflammation on pancreatic cancer.
Zechner D; Radecke T; Amme J; Bürtin F; Albert AC; Partecke LI; Vollmar B
BMC Cancer; 2015 Feb; 15():51. PubMed ID: 25885700
[TBL] [Abstract][Full Text] [Related]
5. Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway.
Zhu M; Zhang Q; Wang X; Kang L; Yang Y; Liu Y; Yang L; Li J; Yang L; Liu J; Li Y; Zu L; Shen Y; Qi Z
Oncotarget; 2016 Dec; 7(51):84190-84200. PubMed ID: 27705937
[TBL] [Abstract][Full Text] [Related]
6. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
Duan W; Qian W; Zhou C; Cao J; Qin T; Xiao Y; Cheng L; Li J; Chen K; Li X; Ma J; Ma Q
Oncol Rep; 2018 Sep; 40(3):1495-1502. PubMed ID: 29956804
[TBL] [Abstract][Full Text] [Related]
7. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
8. α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway.
Schönrogge M; Kerndl H; Zhang X; Kumstel S; Vollmar B; Zechner D
Cell Signal; 2018 Jul; 47():101-108. PubMed ID: 29609037
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
Fujihara S; Kato K; Morishita A; Iwama H; Nishioka T; Chiyo T; Nishiyama N; Miyoshi H; Kobayashi M; Kobara H; Mori H; Okano K; Suzuki Y; Masaki T
Int J Oncol; 2015 May; 46(5):2172-80. PubMed ID: 25709052
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.
Lu R; Yang J; Wei R; Ke J; Tian Q; Yu F; Liu J; Zhang J; Hong T
PLoS One; 2018; 13(6):e0198938. PubMed ID: 29897998
[TBL] [Abstract][Full Text] [Related]
11. Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities.
Rahnasto-Rilla M; Järvenpää J; Huovinen M; Schroderus AM; Ihantola EL; Küblbeck J; Khadeer M; Moaddel R; Lahtela-Kakkonen M
Biomed Pharmacother; 2020 Nov; 131():110701. PubMed ID: 32905943
[TBL] [Abstract][Full Text] [Related]
12. Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro.
Uehara T; Mitsuhashi A; Tsuruoka N; Shozu M
Oncol Rep; 2015 Feb; 33(2):744-50. PubMed ID: 25421433
[TBL] [Abstract][Full Text] [Related]
13. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4.
Cheng G; Lanza-Jacoby S
Biochem Biophys Res Commun; 2015 Sep; 465(1):41-6. PubMed ID: 26225747
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A.
Rupiani S; Guidotti L; Manerba M; Di Ianni L; Giacomini E; Falchi F; Di Stefano G; Roberti M; Recanatini M
Org Biomol Chem; 2016 Nov; 14(46):10981-10987. PubMed ID: 27827510
[TBL] [Abstract][Full Text] [Related]
15. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Zhou G; Yu J; Wang A; Liu SH; Sinnett-Smith J; Wu J; Sanchez R; Nemunaitis J; Ricordi C; Rozengurt E; Brunicardi FC
Curr Mol Med; 2016; 16(1):83-90. PubMed ID: 26695692
[TBL] [Abstract][Full Text] [Related]
16. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.
Li Y; Li L; Zhang G; Wang Y; Chen H; Kong R; Pan S; Sun B
Invest New Drugs; 2018 Feb; 36(1):20-27. PubMed ID: 28875433
[TBL] [Abstract][Full Text] [Related]
17. Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy.
Snima KS; Nair RS; Nair SV; Kamath CR; Lakshmanan VK
J Biomed Nanotechnol; 2015 Jan; 11(1):93-104. PubMed ID: 26301303
[TBL] [Abstract][Full Text] [Related]
18. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.
Saini N; Yang X
Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):133-143. PubMed ID: 29342230
[TBL] [Abstract][Full Text] [Related]
19. Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
Yamana H; Kato K; Kobara H; Fujihara S; Fujita K; Namima D; Fujita N; Kobayashi K; Kamada H; Morishita A; Tsutsui K; Iwama H; Masaki T
Anticancer Res; 2020 Jan; 40(1):121-132. PubMed ID: 31892560
[TBL] [Abstract][Full Text] [Related]
20. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Kato K; Iwama H; Yamashita T; Kobayashi K; Fujihara S; Fujimori T; Kamada H; Kobara H; Masaki T
Oncol Rep; 2016 Mar; 35(3):1582-92. PubMed ID: 26708419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
